March 16th 2023
National Comprehensive Cancer Network guidelines will now include ripretinib as the ideal second-line treatment for patients with unresectable/metastatic gastrointestinal stromal tumors who are intolerant to sunitinib.
February 25th 2023
January 25th 2023
Chemotherapy for Soft-Tissue SarcomasJanuary 15th 2015
In patients with high-risk localized disease, the use of systemic chemotherapy should be strongly considered to delay recurrence and/or reduce the patient’s risk of developing metastatic disease. In patients with metastatic disease, systemic chemotherapy remains the mainstay of treatment.
Chemotherapy in Soft-Tissue Sarcoma: Where Do We Go From Here?January 15th 2015
While the future is bright for the development and investigation of novel chemotherapeutics for treatment of soft-tissue sarcoma, investigators will need to gain better insight into the molecular drivers of pathogenesis, and give continued thoughtful consideration to clinical trial design.
Temsirolimus Tops Bevacizumab in High-Risk RhabdomyosarcomaJune 16th 2014
Patients with first relapse rhabdomyosarcoma treated with a chemotherapy backbone of vinorelbine/cyclophosphamide plus temsirolimus had a superior event-free survival compared to patients treated with the same backbone plus bevacizumab.
Adding Ifosfamide Fails to Improve Survival in SarcomaApril 5th 2014
Combination treatment with ifosfamide and doxorubicin for advanced soft-tissue sarcoma did not improve overall survival compared with treatment with doxorubicin alone, despite improvements in both overall response and progression-free survival.
Mutation Status in GIST Has Little Effect on Imatinib Treatment OutcomesMarch 27th 2014
Pathologic and molecular features of gastrointestinal stromal tumors (GIST) were generally not correlated with outcome in a study involving adjuvant imatinib therapy following resection of the primary tumor.
Outcomes Worse for Single Patients With Soft-Tissue SarcomaMarch 11th 2014
Single patients with soft-tissue sarcoma of the extremities had worse overall survival and were less likely to undergo several important treatment options compared with their married counterparts, according to results of a recent study.
Palliative Treatment Options Scare for Retroperitoneal SarcomasFebruary 12th 2014
Patients with retroperitoneal sarcomas who are unable to obtain complete resection after initial resection are left with few treatment options for palliative therapy, according to the results of a recent study.
HDAC Inhibitor and Imatinib Combo May Inhibit GIST GrowthJanuary 30th 2014
Patients with heavily pretreated metastatic gastrointestinal stromal tumors were able to tolerate combined treatment with the pan-deacetylase inhibitor panobinostat and imatinib, according to the results of a small phase I study.
Extended Surgery for Retroperitoneal Sarcoma: The Key to Maximizing the Potential for Cure and SurvivalJuly 15th 2013
Surgery is the mainstay of treatment for localized soft-tissue sarcoma (STS). It consists primarily of resection of the tumor along with a cuff of surrounding healthy tissue. In limb and trunk wall sarcomas, this basically implies resection of the surrounding soft tissues, which are mainly muscles, subcutaneous fat, and skin. In the retroperitoneum, this necessarily should imply resection of adjacent viscera, even when they are not overtly involved. This is the only way to avoid/minimize the presence of tumor cells at the cut surface (ie, positive microscopic surgical margins). Positive microscopic surgical margins are associated with a higher risk of local failure, distant metastases, and death.[3-6] Moreover, for STS located at critical sites, such as retroperitoneal sarcoma (RPS), positive surgical margins may have a direct impact on survival, favoring the development of inoperable local recurrences. Indeed, unlike with STS arising in the extremities and trunk wall, local control in RPS poses a significant challenge and remains the leading cause of death, particularly in patients with low- to intermediate-grade tumors-roughly 75% of all cases.[8-13] Extending the resection to adjacent uninvolved viscera for primary RPS is the only way to minimize the presence of microscopic surgical margins and hence maximize the chance of cure. In essence, this strategy should often include ipsilateral nephrectomy and colectomy; locoregional peritonectomy and myomectomy (partial/total) of the muscle of the lateral/posterior abdominal wall (usually the psoas) (see Figure); splenectomy and left pancreatectomy, for tumors located on the left upper side; occasionally pancreaticoduodenectomy or hepatectomy, for tumors located on the right side; and vascular and bone resection only if vessels/bone are overtly infiltrated.